Group 1 - Novo Nordisk's stock surged, with an intraday increase of over 10% following the FDA approval of its first oral GLP-1 weight loss drug, Wegovy [1][2] - The oral drug is expected to be launched in early 2026 at a cash price of $149 per month, with potential costs as low as $25 per month for insured patients [1][2] - The CEO of Novo Nordisk emphasized that Wegovy provides a new, convenient treatment option for patients, claiming no other oral GLP-1 therapy matches its weight loss effectiveness [2] Group 2 - The oral formulation is seen as the next growth engine in the weight loss drug market, with Goldman Sachs analysts predicting it could capture 24% of the global market by 2030, valued at approximately $22 billion [2] - The introduction of the oral version is expected to broaden treatment access and encourage more patients to seek treatment [2] - The active ingredient in the oral drug is the same as that in the injectable version, which may enhance patient confidence in its safety and efficacy [2]

Core Insights - Oral GLP-1 weight loss drugs are expected to become a significant product cycle in the biopharmaceutical sector, with market shares projected to reach 24% and 32% by 2030 and 2035, respectively, resulting in market sizes of $22.3 billion and $38.1 billion [2] Group 1: Market Dynamics - Goldman Sachs has removed Pfizer's danuglipron from its weight loss drug market model, previously forecasting sales of $1.2 billion and $1.9 billion for 2030 and 2035 [2] - The market share forecast for Eli Lilly's orforglipron has been increased, with expectations that it will capture half of the market share left by Pfizer, while the other half will be distributed among other oral products [2] - Adjusted risk-adjusted sales forecasts for orforglipron are now $1 billion in 2026, $17.2 billion in 2030, and $24.5 billion in 2035, up from previous estimates of $1 billion, $16.5 billion, and $23.5 billion, respectively [2] Group 2: Competitive Landscape - Goldman Sachs maintains its sales forecast for Novo Nordisk's oral semaglutide at $5.3 billion, indicating that despite orforglipron's anticipated market advantage, there remains market space for oral semaglutide 25mg due to low likelihood of generic drug entry and extended price protection until orforglipron's patent expiration [4] Group 3: Patient Preferences and Pricing - The obesity market is being segmented by BMI and treatment type (oral vs. injectable), with oral medications likely to attract more patients; approximately 50% of patients may prefer oral medications despite lower efficacy compared to injectables [5] - Initial monthly net prices for the first oral drugs (Eli Lilly's orforglipron and Novo Nordisk's oral semaglutide 25mg) are expected to be around $650, decreasing to $457 and $308 by 2030 and 2035, respectively, approaching the pricing of injectable drugs [5]